AAM Issue Brief: Biosimilars Medicare Part D | Association for Accessible Medicines
Stop REMS Abuse - Anti-competitive practices are costing patients billions - you can help!

AAM Issue Brief: Biosimilars Medicare Part D

Increasing Patient Access to Biosimilars in Medicare Part D

Congress should amend the Part D coverage gap discount program to classify biosimilars as “applicable drugs” in the Coverage Gap Discount Program. This change would allow biosimilar manufacturers to pay the 50 percent discounts paid by their brand competitors, and participate on a level playing field to compete for placement on the Part D plan’s formulary. It would reduce both patient out-of-pocket costs and Part D program spending.